Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses-Reference-Cited by-同舟云学术

Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses

Published:2018-04-12 Issue:4 Volume:4 Page:e175245
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Montagut Clara¹²,Argilés Guillem³⁴,Ciardiello Fortunato⁵,Poulsen Thomas T.⁶,Dienstmann Rodrigo³⁴,Kragh Michael⁶,Kopetz Scott⁷,Lindsted Trine⁶,Ding Cliff⁶,Vidal Joana¹,Clausell-Tormos Jenifer⁶,Siravegna Giulia⁸⁹,Sánchez-Martín Francisco J.²,Koefoed Klaus⁶,Pedersen Mikkel W.⁶,Grandal Michael M.⁶,Dvorkin Mikhail¹⁰,Wyrwicz Lucjan¹¹,Rovira Ana²,Cubillo Antonio¹²,Salazar Ramon¹³,Desseigne Françoise¹⁴,Nadal Cristina¹⁵,Albanell Joan¹²¹⁶,Zagonel Vittorina¹⁷,Siena Salvatore¹⁸,Fumi Guglielmo¹⁹,Rospo Giuseppe⁸,Nadler Paul⁶,Horak Ivan D.⁶,Bardelli Alberto⁸⁹,Tabernero Josep³⁴

Affiliation:

1. Medical Oncology Department, Hospital del Mar–CIBERONC, Barcelona, Spain

2. Cancer Research Program, IMIM (Hospital del Mar Research Institute), Barcelona, Spain

3. Medical Oncology Department, Vall d’Hebron University Hospital, Barcelona, Spain

4. Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, CIBERONC, Barcelona, Spain

5. Seconda Università degli Studi di Napoli, Naples, Italy

6. Symphogen A/S, Ballerup, Denmark

7. Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston

8. Candiolo Cancer Institute–FPO, IRCCS, Candiolo, Torino, Italy

9. University of Torino, School of Medicine, Torino, Italy

10. BHI of Omsk Region “Clinical Oncology Dispensary,” Omsk, Russia

11. Centrum Onkologii-Instytut im. M. Sklodowskiej Curie, Warsaw, Poland

12. Centro Integral Oncologico Clara Campa, Madrid, Spain

13. Institut Català d’Oncologia, Institut d’Investigació biomèdica de Bellvitge, CIBERONC, Barcelona, Spain

14. Consultation d'Oncologie Génétique, Centre de Lutte Contre le Cancer Leon Berard, Lyon, France

15. Hospital Clinic of Barcelona, University of Barcelona, Spain

16. Pompeu Fabra University, Barcelona, Spain

17. Medical Oncology Unit 1, Istituto Oncologico Veneto, IRCCS, Padova, Italy

18. Grande Ospedale Metropolitano Niguarda and Università degli Studi di Milano, Milano, Italy

19. Azienda Ospedaliera S. Maria Di Terni, Terni, Italy

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Link

http:///jamaoncology/article-pdf/4/4/e175245/17553275/jamaoncology_montagut_2018_oi_170097.pdf

Reference29 articles.

1. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status.;Van Cutsem;J Clin Oncol,2011

2. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study.;Bokemeyer;Ann Oncol,2011

3. Analysis of KRAS/NRAS mutations in a phase III study of panitumumab with FOLFIRI compared with FOLFIRI alone as second-line treatment for metastatic colorectal cancer.;Peeters;Clin Cancer Res,2015

4. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer.;Misale;Nature,2012

5. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers.;Diaz;Nature,2012

Cited by 103 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An Evolving Landscape: New Therapies for Metastatic Colorectal Cancer;Clinical Colorectal Cancer;2024-08

2. Switching anti-EGFR antibody re-sensitizes head and neck cancer patient following acquired resistance to cetuximab;Cancer Gene Therapy;2024-07-31

3. Targeting cytokine and chemokine signaling pathways for cancer therapy;Signal Transduction and Targeted Therapy;2024-07-22

4. Epidermal Growth Factor Receptor Targeting in Colorectal Carcinoma: Antibodies and Patient-Derived Organoids as a Smart Model to Study Therapy Resistance;International Journal of Molecular Sciences;2024-06-28

5. Navigating through novelties concerning mCRC treatment—the role of immunotherapy, chemotherapy, and targeted therapy in mCRC;Frontiers in Surgery;2024-06-14